CA-ARIBIO-CO.,-LTD.
AriBio Co., Ltd. announced that David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from the completed phase 2 study in patients with mild to moderate Alzheimer’s disease who were treated with 10mg and 30mg of AR1001. AR1001 is a potent PDE5 inhibitor with preliminary efficacy in cognition, and preclinical effects on neuron apoptosis inhibition, promotion of neurogenesis, increase in neuroplasticity, and stimulation of autophagy to remove toxic proteins.
The phase 2 study was a double-blind, randomized, placebo-controlled, multi-center trial to evaluate the safety and preliminary efficacy of AR1001 over 26 and 52 weeks of treatment in patients with mild to moderate Alzheimer’s disease. The trial enrolled 210 patients at 21 research centers in the United States.
Plasma collected from patients at baseline, week 26 and week 52 was analyzed by Quantarix using the Simoa HD-X analyzer. Meaningful, statistically significant changes were found over 52 weeks of treatment in a post-hoc analysis, including a dose dependent decline of pTau181 at 26 weeks, and further declines after 52 weeks of treatment. Patients randomized to 10 and 30 mg AR1001 treatment after 26 weeks of treatment with placebo also demonstrated similar declines in pTau181. Other plasma markers including NfL, GFAP and AB42/40 ratio were also measured but showed minimal change or no statistical differences over baseline levels.
AriBio initiated a phase 3 pivotal trial with 30mg of AR1001 to be administered daily to early and mild Alzheimer’s disease patients in December of 2022. Enrollment is expected to continue through 2024. “This biomarker data helps bolster the positive effects seen in cognition with the high dose of AR1001 in the Phase 2 study in mild AD patients. We will continue to collect both CSF and plasma as part of the phase 3 study to analyze as supportive data,” stated Dr. Greeley.
About AR1001-ADP3-US01
AR1001-ADP3-US01 (NCT05531526) is a Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer’s disease. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the field of medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230331005009/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Symrise and Aplantex Confirm an Agreement to Establish a Partnership14.10.2025 12:00:00 CEST | Press release
Symrise AG ("Symrise") and Aplantex Bio ("Aplantex") agree on a partnership covering new technologies for accessing plant-based molecules as raw material once the molecules of interest have been developed and produced by Aplantex. "We are intrigued by the potential of Aplantex’s innovative green biotechnology process to help us in securing potential access to hard-to-source plant-based molecules in the context of the significant impacts of climate change," underlines Dr. Jakob Ley, director of Biobased Ingredients Research at Symrise. Aplantex has been, since 2024, diligently involved in the research & development work to produce the initial molecule of interest requested by Symrise. "Having already validated our process with the production of Apigenin, Orientin, Vitexin, and Luteolin, four molecules recognized for their antioxidant, anti-inflammatory, antimicrobial, and anti-aging properties, we were able to reach several milestones of Symrise’s validation protocol in record time. We
Europe’s Tech Services Market Slows in Q3, Despite Strong AI-Driven Cloud Demand: ISG Index™14.10.2025 10:00:00 CEST | Press release
Combined market up 5% in Q2, driven by 41% growth in cloud servicesManaged services slumps 25%, as companies remain cautious in the face of macro challenges Europe’s market for technology services and software slowed in the third quarter despite continuing strong demand for AI, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows third-quarter ACV for the combined market (both managed services and cloud-based as-a-service) rose 5 percent, to US $9.7 billion. Although the market has grown for seven consecutive quarters, averaging 14 percent quarterly growth during that span, the rate of growth in the third quarter was the lowest since the second quarter last year. “The market in Europe continues to be buoyed by strong, double-digit growth in cl
euNetworks Delivers New Fully Diverse Long Haul Network Route, Enabling Two Short Paths Connecting Frankfurt to Marseille and Milan14.10.2025 10:00:00 CEST | Press release
The shorter routes from Frankfurt to Marseille and Milan significantly reduce network latency for customers requiring diverse connectivity. The network enhances route diversity in the region, delivering new fibre routing for companies entering Europe via Marseille. euNetworks Group Limited (“euNetworks”), a European critical bandwidth infrastructure company, has today announced the completion of a new long haul fibre network route between Frankfurt and Zurich. This new network enables two short diverse paths between the many submarine cable landings along the Mediterranean coast, and the major data centre market of Frankfurt. The new route completes one of two fully diverse euNetworks long haul routes, with the option to either go via Milan and Zurich or via Marseille, Lyon and Geneva. euNetworks undertook this network investment to increase diversity options for its customers, enabling them to avoid points of failure where routes converge and cross, or otherwise take a long detour via
Hamad International Airport's Senior Operations Manager appointed as CEO of Ancona International Airport14.10.2025 09:00:00 CEST | Press release
Ancona International Airport (“AIA”), a Njord Partners portfolio company, is pleased to announce the appointment of Giorgio Buffa as its new Chief Executive Officer, effective 13 October 2025. Giorgio Buffa joins Ancona from Doha’s Hamad International Airport, where he was the Senior Operations Manager. He brings over 20 years of dedicated experience in the airport and airline industries, having spent his entire career in aviation. He is recognised for driving operational excellence and pioneering sustainable development at Hamad International Airport, which has, for multiple years, been named the "World's Best Airport" by Skytrax, setting new standards in the airport sector. For the past nine years, he has been instrumental in overseeing key operational functions and successfully navigated the COVID-19 period as well as major events such as the FIFA World Cup. Formerly a pilot with Alitalia and Air One, Giorgio has held various senior leadership roles in airport operations, including
PPG introduces PPG MIX‘N’SHAKE automated stirring technology for body shops14.10.2025 08:30:00 CEST | Press release
System improves productivity, reduces waste, enhances color accuracy PPG (NYSE: PPG) today announced the introduction of PPG MIX‘N’SHAKE™ automated stirring technology designed to eliminate traditional manual stirring methods in the automotive refinish industry. The system, which is available globally, improves paint mix consistency, reduces consumable waste and saves time for painters and body shops. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013065453/en/ PPG MIX’N’SHAKE™ automated stirring technology replaces manual stirring processes to ensure a homogenized paint mix, complete color accuracy, and a better workplace. The PPG Mix‘n’Shake system will debut at the EQUIP AUTO trade show in Paris taking place Oct. 14-18. PPG will also showcase its PPG LINQ™ digital ecosystem, which is a finalist for the prestigious EQUIP AUTO Innovation Award. Because the PPG Mix‘n’Shake system eliminates manual stirring, it ensures con
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom